Unknown

Dataset Information

0

A Review of the Past, Present and Future of Cancer-associated Thrombosis Management.


ABSTRACT: Venous thromboembolism (VTE) can have a significant impact on the management, quality of life and mortality of patients with cancer. VTE occurs in 5-20% of patients with cancer, and malignancy is associated with up to 25% of all VTE. It is the second leading cause of death in ambulatory patients with cancer who are receiving chemotherapy. Increased rates of cancer-associated thrombosis are attributed to improved patient survival, increased awareness, surgery, antineoplastic treatments and the use of central venous access devices. Many factors influence cancer-associated thrombosis risk and are broadly categorized into patient-related, cancer-related and treatment-related risks. Direct-acting oral anticoagulants have shown themselves to be at least as effective in preventing recurrent VTE in patients with cancer with symptomatic and incidental VTE. This has led to a change in treatment paradigms so that direct-acting oral anticoagulants are now considered first-line agents in appropriately selected patients. In this article, we review the prior and recent landmark studies that have directed the treatment of cancer-associated thrombosis, and discuss specific factors that affect management as well as future treatment considerations.

SUBMITTER: Ramcharitar RK 

PROVIDER: S-EPMC9870322 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Review of the Past, Present and Future of Cancer-associated Thrombosis Management.

Ramcharitar Randy K RK   Man Louise L   Khaja Minhaj S MS   Barnett Merry Ellen ME   Sharma Aditya A  

Heart international 20220823 2


Venous thromboembolism (VTE) can have a significant impact on the management, quality of life and mortality of patients with cancer. VTE occurs in 5-20% of patients with cancer, and malignancy is associated with up to 25% of all VTE. It is the second leading cause of death in ambulatory patients with cancer who are receiving chemotherapy. Increased rates of cancer-associated thrombosis are attributed to improved patient survival, increased awareness, surgery, antineoplastic treatments and the us  ...[more]

Similar Datasets

| S-EPMC9108694 | biostudies-literature
| S-EPMC8909254 | biostudies-literature
| S-EPMC3721379 | biostudies-literature
| S-EPMC8529297 | biostudies-literature
| S-EPMC10047250 | biostudies-literature
| S-EPMC11588188 | biostudies-literature
| S-EPMC2929629 | biostudies-literature
| S-EPMC8196600 | biostudies-literature
| S-EPMC9436021 | biostudies-literature
| S-EPMC7405018 | biostudies-literature